- Open
- 61.00
- High
- 66.89
- Low
- 59.16
- Close
- 66.89
- Change
- -4.00 (-6.56%)
- Volume
- 18,116
| 13 Aug 2026 | 07:00:05 | AT278 data published in peer-reviewed journal |
| 10 Aug 2026 | 11:32:55 | Holding(s) in Company |
| 28 May 2026 | 14:00:00 | Result of AGM |
| 21 May 2026 | 13:00:00 | Grant of options and PDMR dealing |
| 18 May 2026 | 07:00:10 | Upcoming conference attendance |
| 11 May 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 13 May 2025 | Annual Report and Accounts (to 2024-12-31) |
Arecor Therapeutics plc is a clinical-stage biotech company developing therapeutics aimed at reducing treatment burden and improving outcomes for individuals with diabetes, obesity, and other cardiometabolic diseases. Its lead product, AT278, is an ultra-concentrated ultra-rapid-acting insulin in development, designed to enhance automated insulin delivery systems. Arecor is also working on a novel oral delivery platform for peptides, targeting GLP-1 receptor agonists as its first validation. The company is based in Cambridge, UK.
| 13 Aug 2026 | 07:00:05 | AT278 data published in peer-reviewed journal |
| 10 Aug 2026 | 11:32:55 | Holding(s) in Company |
| 28 May 2026 | 14:00:00 | Result of AGM |
| 21 May 2026 | 13:00:00 | Grant of options and PDMR dealing |
| 18 May 2026 | 07:00:10 | Upcoming conference attendance |
| 11 May 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 13 May 2025 | Annual Report and Accounts (to 2024-12-31) |
Arecor Therapeutics plc is a clinical-stage biotech company developing therapeutics aimed at reducing treatment burden and improving outcomes for individuals with diabetes, obesity, and other cardiometabolic diseases. Its lead product, AT278, is an ultra-concentrated ultra-rapid-acting insulin in development, designed to enhance automated insulin delivery systems. Arecor is also working on a novel oral delivery platform for peptides, targeting GLP-1 receptor agonists as its first validation. The company is based in Cambridge, UK.
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £46m | -0.4% | |
ARECArecor Therapeutics PLC | £25m | -0.0% |
| £13m | +0.5% | |
| £12m | +0.4% | |
| £11m | +2.2% | |
| £10m | -0.5% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £46m | -0.4% | |
ARECArecor Therapeutics PLC | £25m | -0.0% |
| £13m | +0.5% | |
| £12m | +0.4% | |
| £11m | +2.2% | |
| £10m | -0.5% |